Sotorasib and adagrasib have similar mechanisms of action through covalent binding of the cysteine 12 site within the KRAS G12C protein, rendering KRAS inactive and preventing cell proliferation, effectively halting cancer cell progression [44,45]. Here, KRAS is linked to cancer.